A Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results

Simply Wall St.

Apr 13

AdvertisementPhase 3 REVEAL-1 results put elegrobart in focus Viridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2627455812"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627455812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627455812?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-13 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627455812","market":"nz","top_or_hot":-1,"title":"A Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementPhase 3 REVEAL-1 results put elegrobart in focus Viridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/a-look-at-viridian-therapeutics-vrdn-valuation-after-positiv-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-13 19:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/a-look-at-viridian-therapeutics-vrdn-valuation-after-positiv-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementPhase 3 REVEAL-1 results put elegrobart in focus Viridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/a-look-at-viridian-therapeutics-vrdn-valuation-after-positiv-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/a-look-at-viridian-therapeutics-vrdn-valuation-after-positiv-1","article_id":"2627455812","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/a-look-at-viridian-therapeutics-vrdn-valuation-after-positiv-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2627455812","pubTimestamp":1776078744,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Phase 3 REVEAL-1 results put elegrobart in focus\nViridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, a material update that reshapes how you might look at the stock.\nSee our latest analysis for Viridian Therapeutics.\nThe REVEAL-1 update lands after a volatile stretch, with the share price at $14.95, a 7 day share price return of 7.55% but a 90 day share price return of 53.27%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技","VRDN":"Viridian Therapeutics, Inc."},"translate_title":"Reveal-1 3期Elegrobart结果积极后审视Viridian Therapeutics(VRDN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"VRDN":1.5},"content_text":"AdvertisementPhase 3 REVEAL-1 results put elegrobart in focus Viridian Therapeutics (VRDN) just reported statistically significant, positive topline data from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, a material update that reshapes how you might look at the stock. See our latest analysis for Viridian Therapeutics. The REVEAL-1 update lands after a volatile stretch, with the share price at $14.95, a 7 day share price return of 7.55% but a 90 day share price return of 53.27%, while the 1 year total shareholder return of 12.41% sits against a weaker 3 year total shareholder return of 44.17%. This suggests that short term momentum has picked up following the trial data, while longer term holders are still in recovery mode. If elegrobart’s progress has you rethinking where growth in healthcare could come from next, it may be worth scanning a broader set of 31 healthcare AI stocks With elegrobart clearing a key Phase 3 hurdle and Viridian trading at a steep discount to the average analyst price target, the real question is whether this is a reset entry point or whether markets already reflect expectations for future growth. Price-to-Sales of 21.6x: Is it justified? At a last close of $14.95, Viridian trades on a P/S of 21.6x, which lines up with a company that the market is pricing well above typical peer levels. The P/S multiple compares the company’s market value to its $70.8 million of revenue and, for early stage biotechs that are still loss making, it often becomes the key shorthand for how investors are weighing current sales against expectations for future therapies like elegrobart. Here, the valuation signals are mixed. On one hand, Viridian screens as trading at 91.5% below the SWS DCF fair value estimate of $175.61 per share, which points to a very large upside gap if those cash flow projections play out. On the other hand, the current 21.6x P/S is described as expensive compared with both the estimated fair P/S of 0.1x and the US biotechs industry average of 11x, a level the market could move toward if sentiment cools or if revenue does not build as expected. Explore the SWS fair ratio for Viridian Therapeutics Result: Price-to-Sales of 21.6x (OVERVALUED) However, the story can change quickly if future elegrobart data disappoints or if Viridian’s US$281.9 million net loss forces more funding on less friendly terms. Find out about the key risks to this Viridian Therapeutics narrative. Another way to look at value Our DCF model presents a very different perspective compared to the 21.6x P/S ratio. On this view, Viridian trades at $14.95 while the model suggests a fair value of $175.61, which indicates that it may be very undervalued. For you, the question is simple: which signal should carry more weight? Look into how the SWS DCF model arrives at its fair value. VRDN Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 57 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With sentiment split between high expectations and clear risks, it makes sense to move quickly, review the data for yourself, and weigh both sides using the 2 key rewards and 2 important warning signs Looking for more investment ideas? If Viridian has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could round out your portfolio.  Target potential upside by scanning 57 high quality undervalued stocks that pair appealing prices with solid fundamentals and may deserve a closer look before others catch on. Prioritise resilience by checking 73 resilient stocks with low risk scores that score well on stability, so you are not caught off guard when conditions change. Spot future standouts early by reviewing the screener containing 23 high quality undiscovered gems that many investors may be overlooking right now.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}